VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial

Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Randomized Phase Ii ◽

P3-128: Correlation of the epidermal growth factor receptor mutations with clinical outcomes in patients with non–small cell lung cancer treated gefitinib: an exploratory molecular analysis of a prospective phase II study

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000284103.12311.8d ◽

2007 ◽

Vol 2 (8) ◽

pp. S733-S734

Author(s):

Hyewon Lee ◽

Hoyong Sim ◽

Se Hoon Park ◽

Jinny Park ◽

Eun Kyung Cho ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Prospective Phase ◽

Phase II study of tepotinib + gefitinib (TEP+GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non-small cell lung cancer (NSCLC)

Annals of Oncology ◽

10.1093/annonc/mdy292 ◽

2018 ◽

Vol 29 ◽

pp. viii493 ◽

Cited By ~ 11

Author(s):

Y. Cheng ◽

J. Zhou ◽

S. Lu ◽

Y. Zhang ◽

J. Zhao ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Egfr Mutant

55 Randomized phase II clinical trial of cetuximab in combination with cisplatin (C) and vinorelbine (V) or CV alone in patients with advanced epidermal growth factor receptor (EGFR)-expressing non-small-cell lung cancer (NSCLC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(03)90090-5 ◽

2003 ◽

Vol 1 (5) ◽

pp. S21 ◽

Cited By ~ 4

Author(s):

R. Rosell ◽

R. Ramlau ◽

A. Szczesna ◽

C. Daniel ◽

M. Bertrand ◽

...

Keyword(s):

Lung Cancer ◽

Clinical Trial ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Randomized Phase Ii ◽

Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study)

Translational Lung Cancer Research ◽

10.21037/tlcr.2019.08.03 ◽

2019 ◽

Vol 8 (4) ◽

pp. 519-523

Author(s):

Masahiro Iwasaku ◽

Junji Uchino ◽

Tadaaki Yamada ◽

Yusuke Chihara ◽

Takayuki Shimamoto ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Prophylactic Treatment ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Dermatologic Adverse Events

Induction gefitinib followed by standard chemoradiotherapy in locally advanced (LA) non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations: The LOGIK0902/OLCSG0905 intergroup phase II study

Annals of Oncology ◽

10.1093/annonc/mdz436 ◽

2019 ◽

Vol 30 ◽

pp. ix153 ◽

Cited By ~ 1

Author(s):

S. Saeki ◽

K. Hotta ◽

M. Yamaguchi ◽

D. Harada ◽

A. Bessho ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Phase Ii Study ◽

Locally Advanced ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Activating Mutations ◽

Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-015-2784-x ◽

2015 ◽

Vol 76 (1) ◽

pp. 155-161 ◽

Cited By ~ 16

Author(s):

Yusuke Inoue ◽

Naoki Inui ◽

Kazuhiro Asada ◽

Masato Karayama ◽

Hiroyuki Matsuda ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Elderly Patients ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

A phase II study of gefitinib in combination with S-1 plus carboplatin as first-line triplet chemotherapy for patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.e19095 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e19095-e19095

Author(s):

Akihiro Tamiya ◽

Motohiro Tamiya ◽

Takeshi Nakatani ◽

Takayuki Shiroyama ◽

Kanako Kitai ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First- or Second-line Gefitinib Therapy in Unknown Epidermal Growth Factor Receptor Mutants of Non–Small-Cell Lung Cancer Patients Treated in Taiwan

Clinical Lung Cancer ◽

10.1016/j.cllc.2011.03.006 ◽

2011 ◽

Vol 12 (2) ◽

pp. 116-124 ◽

Cited By ~ 6

Author(s):

Chien-Hao Lie ◽

Huang-Chih Chang ◽

Tung-Ying Chao ◽

Yu-Hsiu Chung ◽

Jui-Long Wang ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Lung Cancer Patients ◽

A phase II study of Erbitux (IMC-C225), an Epidermal Growth Factor Receptor (EGFR) blocking ntibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced Non-Small Cell Lung Cancer (NSCLC)

European Journal of Cancer ◽

10.1016/s0959-8049(02)81165-0 ◽

2002 ◽

Vol 38 ◽

pp. S153 ◽

Cited By ~ 2

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Small Cell Lung Cancer ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Phase II Study Of Erlotinib As Third-Line Monotherapy In Patients With Advanced Non-Small-Cell Lung Cancer Without Epidermal Growth Factor Receptor Mutations

10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a4408 ◽

2012 ◽

Author(s):

Shun Matsuura ◽

Naoki Inui ◽

Yuichi Ozawa ◽

Toshihiro Shirai ◽

Mikio Toyoshima ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Small Cell Lung ◽

Epidermal Growth ◽

Third Line